- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02502045
Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's
February 17, 2017 updated by: Yale University
A Study to Examine the Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's Disease
Determine effect and duration of effect of timed therapeutic light compared to control light on parameters of circadian rhythmicity, physiologic plasticity, sleep, and global function in women with Alzheimer's Disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The impact of disturbed sleep on cognition and functional domains is vitally important to study in order to increase our understanding of Alzheimer's disease (AD) phenomenology.
Research has shown that the severity of sleep disturbance and dementia advance in parallel and possibly in a manner amenable to therapeutic intervention.
In AD, sleep disruption is characterized by changes in sleep architecture.
It is our contention that neuropathology specific to AD alters the circadian system at the suprachiasmatic nucleus (SCN).
Environmental light is the most powerful regulator of this circadian system,4,5 and is known to have a significant regulatory effect on pineal melatonin synthesis and secretion via the SCN and multisynaptic pathways downstream from the SCN.
This study will explore further the efficacy of a particular type of therapeutic light intervention in regulating the circadian system in AD, using data analytic methods capable of detecting changes at multiple time scales.
Our central hypothesis is that properly-timed light exposure in individuals with AD will synchronize disorganized circadian and sleep-wake rhythms and improve functional plasticity [approximate entropy (ApEn), fractal dimension (FD)], thereby resulting in increased sleep efficiency (SE), reductions in sleep fragmentation (SF), reduced excessive daytime sleepiness (EDS) and dementia-related behaviors, and improvements in cognition and other daytime behaviors.
Women are nearly twice as likely as men to develop AD due to longer life expectance and emerging evidence.
In light of this increased risk and also to enhance other aspects of biological uniformity in our study, this project will investigate women with AD.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48336
- Botsford Continuing Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- baseline sleep efficiency index < .85
- Mini-Mental State Exam-2 Standard Version (MMSE-2:SV) score of 0-20
- be medically stable
Exclusion Criteria:
- received light treatment in last 3 months
- are totally blind in both eyes, have photosensitivity or photophobia, Parkinsons disease, known untreated sleep apnea or other sleep disorders, seizure disorder, bipolar, schizophrenia, are actively receiving chemotherapy or radiation therapy for cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Morning Simulated Sunlight
Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days.
A flexible window of has been allowed to accommodate participants and care routines.
|
Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
|
|
PLACEBO_COMPARATOR: Non-Therapeutic Red Light
Non-therapeutic red light control at 5 lux will be used as the control condition
|
Non-therapeutic red light control at 5 lux will be used as the control condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in sleep characteristics
Time Frame: 2 weeks
|
Change in sleep characteristics and rest-activity rhythm after 2 weeks of light therapy as measured by actigraphy
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (ACTUAL)
January 1, 2016
Study Completion (ACTUAL)
January 1, 2016
Study Registration Dates
First Submitted
July 16, 2015
First Submitted That Met QC Criteria
July 16, 2015
First Posted (ESTIMATE)
July 17, 2015
Study Record Updates
Last Update Posted (ACTUAL)
February 20, 2017
Last Update Submitted That Met QC Criteria
February 17, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1310012895
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of SaskatchewanCenter of Molecular Immunology, CubaNot yet recruitingMild Alzheimer's Disease | Moderate Alzheimer's DiseaseCanada
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...CompletedDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsCompletedDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedTerminatedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; Alzheimer's Association; Alzheimer...Active, not recruitingPreclinical Alzheimer's Disease | Early Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedTerminatedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
Clinical Trials on Morning Simulated Sunlight
-
Efforia, IncEnrolling by invitation
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompleted
-
National Taiwan University HospitalActive, not recruitingImprovement of Sleep Disorders in Patients With Alzheimer's Disease After Sunlight Exposure Therapy.Alzheimer's Disease (AD) | Sleep Disorders, Circadian RhythmTaiwan
-
Taipei Veterans General Hospital, TaiwanCompletedDepression | StrokeTaiwan
-
Chiayi Christian HospitalNational Cheng Kung UniversityUnknownQuality of Life | Cognitive Impairment | Aging | Depression in Old Age | Nursing HomesTaiwan
-
The Hospital for Sick ChildrenWithdrawn
-
Centre for Evidence-Based Practice, BelgiumBelgian Red CrossCompleted
-
University of MinnesotaThrasher Research FundCompletedFiltered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates (FSPT)Jaundice, NeonatalNigeria
-
University of MinnesotaThrasher Research FundCompletedJaundice, NeonatalNigeria
-
Mayo ClinicCompletedAltitude HypoxiaUnited States